Valuation: Amgen Inc.

Market Cap 226B 7,582B 202B 188B 170B 321B 21,429B 323B 2,252B 881B 11,145B 848B 829B 35,762B P/E 2026 *
26.2x
P/E 2027 * 23.4x
Enterprise Value 267B 8,971B 239B 222B 202B 379B 25,355B 382B 2,664B 1,043B 13,186B 1,003B 981B 42,313B EV / Sales 2026 *
6.85x
EV / Sales 2027 * 6.47x
Free-Float
99.77%
Yield 2026 *
2.44%
Yield 2027 * 2.58%
1 day+1.16%
1 week+2.35%
Current month-1.69%
1 month+8.75%
3 months+14.47%
6 months+21.68%
1 week 3.34
Extreme 3.34
3.5
1 month 3.12
Extreme 3.12
3.58
Current year 2.6
Extreme 2.6
3.68
1 year 2.6
Extreme 2.6
3.68
3 years 2.6
Extreme 2.6
3.68
5 years 2.6
Extreme 2.6
3.68
10 years 2.6
Extreme 2.6
3.68
Manager TitleAgeSince
Chief Executive Officer 63 01/05/2012
Director of Finance/CFO 62 13/05/2010
Chief Tech/Sci/R&D Officer 57 01/06/2023
Director TitleAgeSince
Chairman 63 01/01/2013
Director/Board Member 65 01/01/2012
Director/Board Member 71 01/01/2012
Change 5-day change 1-year change 3-year change Capi.($)
+1.16%+2.35% - - 226B
-1.36%+2.05%+39.95%+91.07% 1,054B
-5.73%-1.71%+30.35%+59.03% 636B
-2.40%+3.24%+19.03%+85.00% 497B
-2.39%+1.75%+65.11%+37.06% 359B
-0.06%+3.12%+23.98%+42.38% 345B
-0.55%+2.42%+13.66%+33.97% 273B
-1.08%+1.12%-6.93%+6.98% 246B
-1.13%+2.54%+41.19%+45.32% 226B
-1.67%+2.56%+25.13%+90.50% 187B
Average -1.68%+3.14%+27.94%+54.59% 424.69B
Weighted average by Cap. -2.04%+3.19%+31.01%+63.26%

Financials

2026 *2027 *
Net sales 38.97B 1,309B 34.81B 32.45B 29.42B 55.36B 3,699B 55.8B 389B 152B 1,924B 146B 143B 6,173B 40.38B 1,356B 36.07B 33.62B 30.48B 57.36B 3,833B 57.81B 403B 158B 1,993B 152B 148B 6,396B
Net income 8.54B 287B 7.63B 7.11B 6.45B 12.13B 811B 12.23B 85.18B 33.35B 422B 32.07B 31.37B 1,353B 9.43B 317B 8.42B 7.85B 7.12B 13.39B 895B 13.5B 94.02B 36.81B 465B 35.4B 34.62B 1,493B
Net Debt 41.36B 1,389B 36.94B 34.44B 31.22B 58.75B 3,926B 59.21B 413B 161B 2,042B 155B 152B 6,551B 35.48B 1,192B 31.69B 29.54B 26.78B 50.4B 3,368B 50.8B 354B 139B 1,751B 133B 130B 5,620B
Projected Income Statement - Annual - Amgen Inc.
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
12/10/26 THB 3.480 +1.16% 5,460
09/10/26 THB 3.440 -1.71% 8,979
08/10/26 THB 3.500 +2.94% 128,046
07/10/26 THB 3.400 -0.58% 14,428
06/10/26 THB 3.420 +0.59% 45,806
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Amgen Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
417.57USD
Average target price
394.77USD
Spread / Average Target
-5.46%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amgen Inc.